Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells - PubMed (original) (raw)
. 2000 Sep 1;96(5):1999-2001.
Affiliations
- PMID: 10961908
Free article
Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells
T Brocker. Blood. 2000.
Free article
Abstract
In current clinical trials, chimeric antibody-like receptors fused to signaling domains derived from TCR-zeta or Fc(epsilon)RIgamma-chain are tested for their ability to lyse tumor cells in vivo. In this study, the function of primary T cells expressing such receptors has been investigated in transgenic mice. These receptors cannot induce proliferation of resting T cells or trigger the production of optimal amounts of cytokines. It is further demonstrated that an initial low presence of cytokine message and protein is disappearing rather fast, whereas the triggering of endogenous TCR/CD3 in the same cells leads to normal prolonged cytokine production. The direct clinical relevance of these findings is further underlined by the increased in vivo tumor rejection by T cells expressing chimeric receptors in presence of exogenous interleukin-2. Therefore, adoptive T-cell therapy using primary T cells transfected with single chain receptors might benefit substantially from the accompanying administration of cytokines. (Blood. 2000;96:1999-2001)
Similar articles
- Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK. Haynes NM, et al. Blood. 2002 Nov 1;100(9):3155-63. doi: 10.1182/blood-2002-04-1041. Blood. 2002. PMID: 12384413 - Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma.
Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ, Darcy PK. Haynes NM, et al. J Immunol. 2001 Jan 1;166(1):182-7. doi: 10.4049/jimmunol.166.1.182. J Immunol. 2001. PMID: 11123291 - Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signalling chains.
Hombach A, Sircar R, Heuser C, Tillmann T, Diehl V, Kruis W, Pohl C, Abken H. Hombach A, et al. Int J Mol Med. 1998 Jul;2(1):99-103. doi: 10.3892/ijmm.2.1.99. Int J Mol Med. 1998. PMID: 9854151 - Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
Nolan KF, Yun CO, Akamatsu Y, Murphy JC, Leung SO, Beecham EJ, Junghans RP. Nolan KF, et al. Clin Cancer Res. 1999 Dec;5(12):3928-41. Clin Cancer Res. 1999. PMID: 10632322 - TCR-gamma delta cells in CD3 zeta-deficient mice contain Fc epsilon RI gamma in the receptor complex but are specifically unresponsive to antigen.
Khattri R, Sperling AI, Qian D, Fitch FW, Shores EW, Love PE, Bluestone JA. Khattri R, et al. J Immunol. 1996 Sep 15;157(6):2320-7. J Immunol. 1996. PMID: 8805629
Cited by
- Programmable synthetic receptors: the next-generation of cell and gene therapies.
Teng F, Cui T, Zhou L, Gao Q, Zhou Q, Li W. Teng F, et al. Signal Transduct Target Ther. 2024 Jan 3;9(1):7. doi: 10.1038/s41392-023-01680-5. Signal Transduct Target Ther. 2024. PMID: 38167329 Free PMC article. Review. - Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective.
Goldsmith SR, Ghobadi A, Dipersio JF, Hill B, Shadman M, Jain T. Goldsmith SR, et al. Transplant Cell Ther. 2022 Nov;28(11):727-736. doi: 10.1016/j.jtct.2022.07.015. Epub 2022 Jul 22. Transplant Cell Ther. 2022. PMID: 35878743 Free PMC article. Review. - Engineering CAR T cells for enhanced efficacy and safety.
Wu Y, Huang Z, Harrison R, Liu L, Zhu L, Situ Y, Wang Y. Wu Y, et al. APL Bioeng. 2022 Jan 18;6(1):011502. doi: 10.1063/5.0073746. eCollection 2022 Mar. APL Bioeng. 2022. PMID: 35071966 Free PMC article. Review. - CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them.
Vanhooren J, Dobbelaere R, Derpoorter C, Deneweth L, Van Camp L, Uyttebroeck A, De Moerloose B, Lammens T. Vanhooren J, et al. Hemasphere. 2023 Aug 18;7(9):e937. doi: 10.1097/HS9.0000000000000937. eCollection 2023 Sep. Hemasphere. 2023. PMID: 37674860 Free PMC article. Review. - Therapeutic T cell engineering.
Sadelain M, Rivière I, Riddell S. Sadelain M, et al. Nature. 2017 May 24;545(7655):423-431. doi: 10.1038/nature22395. Nature. 2017. PMID: 28541315 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources